Discovery Programs - RAPT Therapeutics

A PROPRIETARY DISCOVERY AND DEVELOPMENT ENGINE
THAT MAKES ALL THE DIFFERENCE

Immunology
Computational Biology

Identification of critical immune drivers
Biomarker discovery

Advanced Drug Discovery

Structure-enabled drug design
Very rapid cycle times
Early functional testing in disease-relevant human cellular models

Data-Driven Patient Selection

Patient selection and enrichment in Phase 1/2 trials

Nimble Clinical Execution

Rapid path to proof-of-concept with patient selection strategies

Our proprietary discovery engine relies on our deep expertise in immunology and chemistry, supported by strong computational biology and the ability to exploit difficult targets.

The key pillars of our discovery and development engine are the following:

Computationally Driven Disease Target and Biomarker Identification. We use proprietary methods to identify targets that we believe have a high propensity to drive the immune response in disease states, such as oncology and inflammatory disorders, by computationally screening a combination of proprietary and public databases. Through this process, we also identify biomarkers that can guide our clinical development strategy and increase the probability of clinical success.
Efficient Design of Small-Molecule Drug Properties. The key to our rapid discovery of small molecules is our use of structure and pharmacophore-based drug design strategies, and machine-learning assisted structure-activity-relationships to improve potency, selectivity and pharmacokinetic properties, along with early testing in physiologically relevant immune assays to rapidly identify highly selective, orally administered small molecules. This seamless integration of biology, chemistry and pharmacokinetic disciplines allows for rapid cycle times and quick iterations between hypothesis and compound selection.

Data-Driven Patient Selection. A key strategy for every program is to identify a patient selection and enrichment approach. Our proprietary discovery engine enables enrichment and prospective selection of patients in our early clinical trials that we believe increase the probability of clinical success. Using proprietary and public databases, we can mine contextually rich molecular and clinical data from disease tissues to identify tumor types and inflammatory disease indications that we believe will be most likely to respond to our therapeutic agents.
Nimble Clinical Execution. We believe our precision medicine approach enables a rapid path to proof-of-concept and the potential for regulatory approval.

We believe that the drug candidates generated from this engine, if approved, will significantly improve the treatment paradigms and outcomes for patients, by fundamentally modulating the immune responses in a range of cancers and inflammatory diseases.

COMMITTED TO GROUNDBREAKING DRUG DISCOVERY

A PROPRIETARY DISCOVERY AND DEVELOPMENT ENGINETHAT MAKES ALL THE DIFFERENCE

A PROPRIETARY DISCOVERY AND DEVELOPMENT ENGINE
THAT MAKES ALL THE DIFFERENCE